These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)? Steensma DP Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699 [TBL] [Abstract][Full Text] [Related]
5. Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia-related changes: A single institution experience. Gao L; Hyter S; Zhang D; Kelting S; Woodroof J; Abdallah AO; Yacoub A; McGuirk J; Abdelhakim H; Godwin AK; Cui W Int J Lab Hematol; 2022 Aug; 44(4):738-749. PubMed ID: 35352484 [TBL] [Abstract][Full Text] [Related]
6. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes. Nakajima H Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100 [TBL] [Abstract][Full Text] [Related]
14. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433 [TBL] [Abstract][Full Text] [Related]
15. Epigenetics of myelodysplastic syndromes. Itzykson R; Fenaux P Leukemia; 2014 Mar; 28(3):497-506. PubMed ID: 24247656 [TBL] [Abstract][Full Text] [Related]
16. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis. Matos A; Magalhães SMM; Rauh MJ Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175 [TBL] [Abstract][Full Text] [Related]
17. Targeting Immune Signaling Pathways in Clonal Hematopoiesis. Azrakhsh NA; Mensah-Glanowska P; Sand K; Kittang AO Curr Med Chem; 2019; 26(28):5262-5277. PubMed ID: 30907306 [TBL] [Abstract][Full Text] [Related]
18. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes. Stankov K; Stankov S; Katanic J Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023 [TBL] [Abstract][Full Text] [Related]
19. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults. Babushok DV; Bessler M; Olson TS Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794 [TBL] [Abstract][Full Text] [Related]
20. ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications. Valent P Pathobiology; 2019; 86(1):30-38. PubMed ID: 29860246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]